BioNTech's T-Pam Data Sets Stage for Pivotal 2026 FDA Submission

BioNTech's T-Pam (BNT323) posts strong Phase 2 data in advanced endometrial cancer, doubling survival. Analysts raise targets as company eyes 2026 FDA filing.

BioNTech's strategic pivot from a vaccine maker to an oncology-focused biotech is gaining tangible momentum. The company's latest clinical trial results for its antibody-drug conjugate T-Pam, also known as BNT323/DB-1303, have delivered compelling efficacy in advanced endometrial cancer, prompting analysts to reaffirm bullish stances and setting a clear path toward a regulatory filing next year.

The data, presented at the Society of Gynecologic Oncology's annual meeting in San Juan, Puerto Rico, showed a confirmed objective response rate of 47.9% in evaluable patients. This marks a substantial leap over the approximately 15% response rate typical for standard chemotherapy in this setting. For a key subgroup of patients who had previously failed checkpoint inhibitor therapy, the response rate was even higher at 49.3%. In patients with strong HER2 expression, the rate soared to 73.1%.

Beyond response rates, the therapy nearly doubled median progression-free survival to 8.1 months from a historical benchmark of around four months for chemotherapy. The safety profile was deemed manageable, with serious treatment-related adverse events (Grade 3 or higher) occurring in 46.9% of patients. Grade 3 or higher pneumonitis was observed in 4.8% of cases.

Wall Street took immediate notice of the robust dataset. Analysts at BofA Securities confirmed their Buy rating and nudged their price target up from $128 to $130. Morgan Stanley also increased its target slightly, moving from $125 to $126 while maintaining an Overweight rating. Berenberg Bank similarly reiterated its Buy recommendation. According to MarketBeat, the average analyst price target stands at $133.13, a significant premium to the recent share price of around €84.25. The stock gained over 8% on a weekly basis following the news, approaching its 50-day moving average near €85.

The strong Phase 2 results form the foundation for BioNTech's planned Biologics License Application (BLA) submission to the U.S. FDA, scheduled for the 2026 calendar year. A global Phase 3 confirmatory trial, named Fern-EC-01, is already underway, directly comparing T-Pam to standard chemotherapy. While the market for this specific cancer indication is considered commercially modest, analysts view a potential approval as a critical strategic beachhead. It would allow BioNTech to establish the necessary commercial infrastructure for future, larger oncology markets.

The company's broader pipeline continues to advance. Alongside BNT323, two other candidates, Gotistobart and Pumitamig, are in Phase 3 development. Investors will get an update on the company's financial position with the release of Q1 2026 figures on May 5. The virtual Annual General Meeting on May 15 will see shareholders vote on several proposals, including an expansion of the supervisory board and the creation of new authorized capital of up to €129.5 million.